| Olivia Saturno Kates, MD | |
|
601 N Caroline St # 390, Baltimore, MD 21287-0006 | |
| (443) 287-6217 | |
| (410) 955-9788 |
| Full Name | Olivia Saturno Kates |
|---|---|
| Gender | Female |
| Speciality | Infectious Disease |
| Experience | 9 Years |
| Location | 601 N Caroline St # 390, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881089399 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | D91042 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
The impact vitamin A has on newborns is virtually unknown, but Penn State nutrition researchers have published two papers that may provide a framework for future investigations of the vitamin and neonatal health.
BioteTrubion Pharmaceuticals, Inc. and Facet ch Corp. today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting.
Australian researchers have defined some key characteristics of the metabolically healthy obese - those obese individuals who remain free from type 2 diabetes and other disorders that usually associate with obesity. Their findings have implications for the treatment of type 2 diabetes, insulin resistance and obesity.
Biomedical scientists have revealed the inner workings of a group of proteins that help to switch critical genes on and off during blood-cell production, in a finding that could lead to the development of new and improved cancer drugs.
› Verified 5 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
The impact vitamin A has on newborns is virtually unknown, but Penn State nutrition researchers have published two papers that may provide a framework for future investigations of the vitamin and neonatal health.
BioteTrubion Pharmaceuticals, Inc. and Facet ch Corp. today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting.
Australian researchers have defined some key characteristics of the metabolically healthy obese - those obese individuals who remain free from type 2 diabetes and other disorders that usually associate with obesity. Their findings have implications for the treatment of type 2 diabetes, insulin resistance and obesity.
Biomedical scientists have revealed the inner workings of a group of proteins that help to switch critical genes on and off during blood-cell production, in a finding that could lead to the development of new and improved cancer drugs.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Olivia Saturno Kates, MD 6201 Greenleigh Ave, Middle River, MD 21220-2004 Ph: (410) 933-6423 | Olivia Saturno Kates, MD 601 N Caroline St # 390, Baltimore, MD 21287-0006 Ph: (443) 287-6217 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
The impact vitamin A has on newborns is virtually unknown, but Penn State nutrition researchers have published two papers that may provide a framework for future investigations of the vitamin and neonatal health.
BioteTrubion Pharmaceuticals, Inc. and Facet ch Corp. today announced the presentation of positive data from a phase 1 study of TRU-016 in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) at the 2009 American Society of Hematology (ASH) Annual Meeting.
Australian researchers have defined some key characteristics of the metabolically healthy obese - those obese individuals who remain free from type 2 diabetes and other disorders that usually associate with obesity. Their findings have implications for the treatment of type 2 diabetes, insulin resistance and obesity.
Biomedical scientists have revealed the inner workings of a group of proteins that help to switch critical genes on and off during blood-cell production, in a finding that could lead to the development of new and improved cancer drugs.
› Verified 5 days ago
Dr. Leonard Anang Sowah, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 22 S Greene St, Baltimore, MD 21201 Phone: 410-706-4619 Fax: 410-706-2062 | |
Dr. Bhavandeep Singh Bajaj, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 3345 Wilkens Avenue, Suite L10, Baltimore, MD 21229 Phone: 410-644-4444 Fax: 410-644-4484 | |
Dr. Yonas Sisay, M.D. Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 822 Guilford Ave, #100, Baltimore, MD 21202 Phone: 410-385-9672 | |
Dr. Stephen John Witanowski, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 2700 Quarry Lake Dr, Suite 280, Baltimore, MD 21209 Phone: 410-469-5544 Fax: 410-585-2867 | |
Dr. Susrutha Kotwal, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4940 Eastern Ave, Mfl Bldg, West Tower, 6th Floor, Baltimore, MD 21224 Phone: 410-550-5018 | |
Dr. Mitesh G Trambadia, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 6701 N Charles St Ste 5218, Baltimore, MD 21204 Phone: 443-849-3786 | |
Ronak K Patel, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 201 E University Pkwy, Baltimore, MD 21218 Phone: 410-554-2000 |